311 related articles for article (PubMed ID: 33946592)
1. Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).
Diquigiovanni C; Bonora E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946592
[TBL] [Abstract][Full Text] [Related]
2. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
[TBL] [Abstract][Full Text] [Related]
3. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
4. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
5. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.
Capezzone M; Marchisotta S; Cantara S; Busonero G; Brilli L; Pazaitou-Panayiotou K; Carli AF; Caruso G; Toti P; Capitani S; Pammolli A; Pacini F
Endocr Relat Cancer; 2008 Dec; 15(4):1075-81. PubMed ID: 18832444
[TBL] [Abstract][Full Text] [Related]
6. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
7. Familial nonmedullary thyroid carcinoma.
Mazeh H; Sippel RS
Thyroid; 2013 Sep; 23(9):1049-56. PubMed ID: 23734600
[TBL] [Abstract][Full Text] [Related]
8. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.
Cirello V
Minerva Endocrinol (Torino); 2021 Mar; 46(1):5-20. PubMed ID: 33045820
[TBL] [Abstract][Full Text] [Related]
9. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.
Park YJ; Ahn HY; Choi HS; Kim KW; Park DJ; Cho BY
Thyroid; 2012 Apr; 22(4):356-62. PubMed ID: 22280228
[TBL] [Abstract][Full Text] [Related]
10. Genetic susceptibility to hereditary non-medullary thyroid cancer.
Kamani T; Charkhchi P; Zahedi A; Akbari MR
Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
[TBL] [Abstract][Full Text] [Related]
11. Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer.
McKay JD; Thompson D; Lesueur F; Stankov K; Pastore A; Watfah C; Strolz S; Riccabona G; Moncayo R; Romeo G; Goldgar DE
J Med Genet; 2004 Jun; 41(6):407-12. PubMed ID: 15173224
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
13. The impact of family history on non-medullary thyroid cancer.
Nixon IJ; Suárez C; Simo R; Sanabria A; Angelos P; Rinaldo A; Rodrigo JP; Kowalski LP; Hartl DM; Hinni ML; Shah JP; Ferlito A
Eur J Surg Oncol; 2016 Oct; 42(10):1455-63. PubMed ID: 27561845
[TBL] [Abstract][Full Text] [Related]
14. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
[TBL] [Abstract][Full Text] [Related]
15. Familial nonmedullary thyroid cancer: a review of the genetics.
Khan A; Smellie J; Nutting C; Harrington K; Newbold K
Thyroid; 2010 Jul; 20(7):795-801. PubMed ID: 20465534
[TBL] [Abstract][Full Text] [Related]
16. FAMILIAL NON-MEDULLARY THYROID CARCINOMA.
Guda BB; Komisarenko II; Ostafiichuk MV; Tronko MD
Exp Oncol; 2023 Jun; 45(1):70-78. PubMed ID: 37417280
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
18. An update on familial nonmedullary thyroid cancer.
Ammar SA; Alobuia WM; Kebebew E
Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
[TBL] [Abstract][Full Text] [Related]
19. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
[TBL] [Abstract][Full Text] [Related]
20. Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families.
Tavarelli M; Russo M; Terranova R; Scollo C; Spadaro A; Sapuppo G; Malandrino P; Masucci R; Squatrito S; Pellegriti G
Front Endocrinol (Lausanne); 2015; 6():117. PubMed ID: 26284028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
